Targeted Oncology Library Entry

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Small-Molecule Targeted Therapies DMPK and Bioanalytical Services

Creative Proteomics provides DMPK, LC-MS/MS bioanalysis, metabolite profiling, tumor exposure, and pathway-linked biomarker support for small-molecule targeted therapy research. This section helps researchers explore analytical strategies for tyrosine kinase inhibitors, CDK inhibitors, mTOR / PI3K pathway inhibitors, targeted protein degraders, and related targeted oncology compounds.

Small-molecule targeted therapy studies usually focus on whether a compound reaches the relevant tumor or cellular compartment, maintains sufficient exposure, and modulates the intended pathway. Workflows may require parent-drug quantification, metabolite profiling, tumor-to-plasma comparison, intracellular analyte analysis, CYP / transporter support, pathway biomarker alignment, or PK/PD interpretation.

Explore Targeted Therapy Classes Explore Related Services

Target AccessPlasma, tumor, tissue, cell lysate, and intracellular exposure support.

Pathway ModulationKinase, CDK, PI3K-AKT-mTOR, and degradation-linked biomarkers.

PK/PD ContextParent–metabolite relationships, DDI behavior, resistance, and response timing.

Targeted Therapy Study Logic Exposure → Target → Response

🎯

Targeted Compound ClassTKIs, CDK inhibitors, mTOR / PI3K inhibitors, degraders, and related oncology compounds

📍

Target-Site ExposurePlasma, tumor homogenate, tissue, cell lysate, or intracellular concentration data

🧬

Pathway EngagementPhosphorylation markers, cell-cycle signals, target protein abundance, or degradation response

📊

PK/PD InterpretationExposure–pathway response, adaptive signaling, resistance markers, and time-course readouts

Targeted Therapy Library

Explore Small-Molecule Targeted Therapy Classes

TKI

Tyrosine Kinase Inhibitors (TKIs)

TKI studies often connect parent-drug and metabolite exposure with tumor distribution, CYP / transporter behavior, phosphorylation markers, and resistance context.

Parent-drug quantification
Tumor and plasma exposure
Metabolite profiling
Pathway marker alignment

Explore →

CDK

CDK Inhibitors

CDK inhibitor workflows may combine exposure measurement with tumor access, cell-associated analytes, pRb modulation, Ki-67, and cell-cycle readouts.

Parent-drug quantification
Tumor exposure
Cell-associated analytes
Cell-cycle markers

Explore →

PI3K

mTOR / PI3K Pathway Inhibitors

PI3K-AKT-mTOR pathway studies may pair parent-drug and tissue exposure with pAKT, pS6, p4EBP1, and downstream signaling readouts.

Parent-drug exposure
Tissue distribution
Metabolite profiling
PK/PD pathway markers

Explore →

TPD

Targeted Protein Degraders

Degrader studies may require intracellular exposure, metabolic stability, matrix-effect support, target protein abundance, and exposure–degradation kinetics.

Parent degrader quantification
Intracellular exposure
Target protein abundance
Degradation kinetics

Explore →

Research Questions in Targeted Therapy Studies

Does Exposure Reach the Target and Modulate the Pathway?

Small-molecule targeted therapy workflows are usually designed around target access, pathway modulation, and exposure–response interpretation rather than direct cytotoxic damage alone.

Is plasma exposure enough?Tumor homogenate, tissue, cell lysate, or intracellular methods may be needed when systemic exposure does not represent target-site access.

Is pathway response measured?Phosphorylation markers, cell-cycle markers, target protein abundance, or pathway suppression readouts may be paired with exposure data.

Are metabolites important?MetID, metabolite profiling, and parent–metabolite analysis may be needed when circulating or exposure-relevant metabolites are expected.

Is CYP, transporter, or DDI support needed?CYP metabolism, transporter behavior, or combination regimens can change exposure and should be considered in selected study designs.

Does the compound need intracellular analysis?Targeted protein degraders and some pathway inhibitors may require cell-associated or intracellular exposure assessment.

Is PK/PD interpretation required?Exposure may need to be interpreted with target engagement, pathway response, resistance markers, or degradation kinetics.

Exposure • Target Engagement • Pathway Response

Connecting Exposure with Target Engagement and Pathway Response

Targeted oncology bioanalysis is most useful when concentration data are linked to target-site biology. A plasma PK curve may describe systemic exposure, but these studies often need tumor exposure, intracellular access, pathway biomarker response, and PK/PD interpretation.

Systemic exposureQuantify parent compound and relevant metabolites in plasma, serum, or time-course sample sets.

→

Target-site accessEvaluate tumor, tissue, cell lysate, or intracellular exposure when pathway access is central.

Pathway modulationMeasure kinase signaling, cell-cycle response, mTOR / PI3K suppression, or target protein depletion.

→

Response contextInterpret phosphorylation markers, resistance signals, protein abundance, or degradation kinetics.

DMPK variablesCYP metabolism, transporters, parent–metabolite ratios, DDI behavior, and matrix effects.

→

Study outputMechanism-aware exposure data for targeted oncology research workflows.

Targeted Therapy Research Focus and Potential Readouts

Research Focus	Potential Analytical or Response Readouts
Kinase pathway inhibition	Parent drug, metabolites, tumor exposure, phosphoprotein markers
CDK pathway modulation	Parent drug, pRb, Ki-67, cyclin markers, cell-cycle readouts
PI3K-AKT-mTOR suppression	Parent drug, pAKT, pS6, p4EBP1, pathway feedback markers
Targeted protein degradation	Parent degrader, intracellular exposure, target protein abundance, degradation kinetics
Parent–metabolite relationship	Parent compound, metabolites, parent–metabolite ratio
DDI or transporter effects	CYP metabolism, transporter behavior, combination-regimen exposure

Bioanalytical and DMPK Service Options

Service Modules for Small-Molecule Targeted Therapy Studies

Service modules can be selected based on target class, compound structure, expected metabolites, tumor exposure requirements, intracellular access, concentration range, and biomarker-linked objective.

Parent Drug Quantification

Support LC-MS/MS-based quantification of targeted oncology compounds in plasma, serum, tissue, tumor homogenates, cell lysates, or other matrices.

Parent compound quantification
Plasma, tumor, tissue, or cell-associated samples
Time-course sample analysis
Matrix-specific method development
Combination study support

Metabolite Profiling and MetID

Identify and quantify exposure-relevant metabolites, including CYP-related products, oxidative metabolites, and circulating metabolites.

Phase I / II metabolite profiling
Metabolite identification
Parent–metabolite ratio analysis
Metabolic stability support
LC-MS/MS or HRMS workflows

Tumor, Tissue, and Intracellular Exposure

Assess exposure beyond plasma when tumor penetration, tissue distribution, or intracellular target access is central to the study.

Tumor homogenate bioanalysis
Tissue distribution support
Plasma-to-tumor comparison
Cell lysate or intracellular analysis
Matrix-effect evaluation

Pathway Biomarker and PK/PD Support

Pair exposure analysis with readouts for target engagement, pathway suppression, cell-cycle modulation, or protein degradation.

Phosphorylation marker support
Kinase pathway biomarker alignment
Cell-cycle marker support
Target protein abundance
Exposure–response interpretation

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →

Small-Molecule Targeted Therapies DMPK and Bioanalytical Services

Explore Small-Molecule Targeted Therapy Classes

Tyrosine Kinase Inhibitors (TKIs)

CDK Inhibitors

mTOR / PI3K Pathway Inhibitors

Targeted Protein Degraders

Does Exposure Reach the Target and Modulate the Pathway?

Connecting Exposure with Target Engagement and Pathway Response

Targeted Therapy Research Focus and Potential Readouts

Service Modules for Small-Molecule Targeted Therapy Studies

Parent Drug Quantification

Metabolite Profiling and MetID

Tumor, Tissue, and Intracellular Exposure

Pathway Biomarker and PK/PD Support

Relevant Services for Small-Molecule Targeted Therapy Projects

Ready to Quantify Your Lead Compound or Metabolite?